| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Isoindigotin does not have a classical drug target. Its primary uses are in materials science and organic electronics. As an electron-accepting building block, it is used in the synthesis of conjugated polymers for applications such as organic photovoltaics and field-effect transistors. Its strong electron-withdrawing properties make it suitable for these applications.
|
|---|---|
| ln Vitro |
Isoindigotin is not typically used in pharmacological activity assays. Its properties are evaluated in the context of materials science and organic electronics. Its electron-accepting properties and ability to form conjugated polymers are characterized using techniques such as cyclic voltammetry, UV-Vis spectroscopy, and organic field-effect transistor measurements.
|
| ln Vivo |
Isoindigotin is not used as a drug and does not have in vivo pharmacological activity. Its effects are observed in materials applications where it is used as a building block for organic electronic devices. It is not administered to animals or humans for therapeutic purposes.
|
| Enzyme Assay |
As an electron-accepting building block, isoindigotin does not have a typical enzyme/receptor binding assay. Its properties are assessed based on its electrochemical and optical characteristics. It is not used in standard pharmacological binding assays.
|
| Cell Assay |
Isoindigotin is not typically used in cell-based assays. Its applications are primarily in materials science and organic electronics. The compound's effects on cells are not a primary focus of study, as it is not intended for biological or therapeutic use.
|
| Animal Protocol |
Isoindigotin is not used in animal experiments for pharmacological purposes. Its effects are studied in the context of materials science, where it is used as a component in electronic devices. Animal studies are not relevant to its primary applications.
|
| ADME/Pharmacokinetics |
Isoindigotin has a molecular weight of 262.26 and a molecular formula of C16H10N2O2. It is a solid with a brown to reddish-brown powder appearance. Its purity is typically ≥98%. Its physical properties, such as its electron-accepting ability and stability, are characterized for its use in organic electronics.
|
| Toxicity/Toxicokinetics |
Toxicological data for isoindigotin is not detailed in the provided sources. As a dye and material science compound, it is not intended for human use. Standard safety precautions should be followed when handling. Its toxicity is not a primary focus of its applications.
|
| References |
Wu KM, Zhang MY, Fang Z, Huang L. [Potential antileukemic agents, synthesis of derivatives of indirubin, indigo, and isoindigotin]. Yao Xue Xue Bao. 1985 Nov;20(11):821-6. Chinese. PubMed PMID: 3869774.
|
| Additional Infomation |
Reports indicate that Isatis tinctoria contains isoindigo, and relevant data is available for reference.
Isoindigotin (isoindigo) is an electron-accepting building block used in the synthesis of donor-acceptor conjugated polymers for organic photovoltaics and field-effect transistors. It has two lactam rings and strong electron-withdrawing properties. It exhibits high mobility and good environmental stability in FETs. The compound is used for dyeing and pigment preparation. It is available from various chemical suppliers for research and industrial purposes. |
| Molecular Formula |
C16H10N2O2
|
|---|---|
| Molecular Weight |
262.2628
|
| Exact Mass |
262.074
|
| CAS # |
476-34-6
|
| Related CAS # |
476-34-6;
|
| PubChem CID |
164610
|
| Appearance |
Brown to reddish brown solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
576.3±50.0 °C at 760 mmHg
|
| Flash Point |
245.1±30.3 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.709
|
| LogP |
1.25
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
585
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1/C(=C2/C3C(=CC=CC=3)NC/2=O)/C2C(=CC=CC=2)N1
|
| InChi Key |
VBMISAYWIMDRCV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H10N2O2/c19-15-13(9-5-1-3-7-11(9)17-15)14-10-6-2-4-8-12(10)18-16(14)20/h1-8,17,19H
|
| Chemical Name |
3-(2-hydroxy-1H-indol-3-yl)indol-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~95.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8130 mL | 19.0650 mL | 38.1301 mL | |
| 5 mM | 0.7626 mL | 3.8130 mL | 7.6260 mL | |
| 10 mM | 0.3813 mL | 1.9065 mL | 3.8130 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
